StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)

Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –

ADMA Biologics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ADMA Biologics's operating income for the twelve months ending Jun 30, 2026 was $224.48M, up 44.2% year over year. For fiscal 2025 it was $191.44M, up 37.7% from the year before. The highest annual figure on record is $191.44M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$191.44M+37.7%
FY2024Dec 31, 2024$138.98M+542.5%
FY2023Dec 31, 2023$21.63M–
FY2022Dec 31, 2022-$39.37M–
FY2021Dec 31, 2021-$58.37M–
FY2020Dec 31, 2020-$64.91M–
FY2019Dec 31, 2019-$41.42M–
FY2018Dec 31, 2018-$60.29M–
FY2017Dec 31, 2017-$39.31M–
FY2016Dec 31, 2016-$17.33M–
FY2015Dec 31, 2015-$15.51M–
FY2014Dec 31, 2014-$16.02M–
FY2013Dec 31, 2013-$15.04M–
FY2012Dec 31, 2012-$7.91M–
FY2011Dec 31, 2011-$4.62M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$52.45M+22.5%
Q1 FY2026Mar 31, 2026$58.27M+67.1%
Q4 FY2025Dec 31, 2025$62.75M+63.7%
Q3 FY2025Sep 30, 2025$51.01M+28.7%
Q2 FY2025Jun 30, 2025$42.80M+9.2%
Q1 FY2025Mar 31, 2025$34.88M+59.9%
Q4 FY2024Dec 31, 2024$38.32M+169.3%
Q3 FY2024Sep 30, 2024$39.64M+356.4%
Q2 FY2024Jun 30, 2024$39.20M–
Q1 FY2024Mar 31, 2024$21.82M–
Q4 FY2023Dec 31, 2023$14.23M–
Q3 FY2023Sep 30, 2023$8.69M–
Q2 FY2023Jun 30, 2023-$473.00K–
Q1 FY2023Mar 31, 2023-$813.00K–
Q4 FY2022Dec 31, 2022-$6.06M–
Q3 FY2022Sep 30, 2022-$9.32M–
Q2 FY2022Jun 30, 2022-$9.17M–
Q1 FY2022Mar 31, 2022-$14.82M–
Q4 FY2021Dec 31, 2021-$13.19M–
Q3 FY2021Sep 30, 2021-$14.44M–
Q2 FY2021Jun 30, 2021-$15.58M–
Q1 FY2021Mar 31, 2021-$15.16M–
Q4 FY2020Dec 31, 2020-$17.22M–
Q3 FY2020Sep 30, 2020-$13.80M–
Q2 FY2020Jun 30, 2020-$17.12M–
Q1 FY2020Mar 31, 2020-$16.77M–
Q4 FY2019Dec 31, 2019-$7.83M–
Q3 FY2019Sep 30, 2019-$9.05M–
Q2 FY2019Jun 30, 2019-$11.34M–
Q1 FY2019Mar 31, 2019-$13.21M–
Q4 FY2018Dec 31, 2018-$16.55M–
Q3 FY2018Sep 30, 2018-$13.79M–
Q2 FY2018Jun 30, 2018-$13.42M–
Q1 FY2018Mar 31, 2018-$16.53M–
Q4 FY2017Dec 31, 2017-$10.54M–
Q3 FY2017Sep 30, 2017-$14.43M–
Q2 FY2017Jun 30, 2017-$8.40M–
Q1 FY2017Mar 31, 2017-$5.94M–
Q4 FY2016Dec 31, 2016-$3.94M–
Q3 FY2016Sep 30, 2016-$3.74M–

More ADMA Biologics figures

See a number that looks wrong?